MadagascarTuberculosis profile
Population  2015 24 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 12 (7.1–18) 49 (29–75)
Mortality (HIV+TB only) 1.5 (1.3–1.8) 6.3 (5.2–7.4)
Incidence  (includes HIV+TB) 57 (37–82) 236 (153–337)
Incidence (HIV+TB only) 3.6 (2.2–5.4) 15 (9.1–22)
Incidence (MDR/RR-TB)** 0.46 (0.12–0.81) 1.9 (0.5–3.3)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 3.9 (1.7–6.1) 20 (9.2–31) 24 (11–37)
Males 4 (2.4–5.6) 29 (20–38) 33 (22–44)
Total 7.9 (5.1–11) 49 (37–62) 57 (37–82)
TB case notifications, 2015  
Total cases notified 29 939
Total new and relapse 29 464
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 33%
          - % pulmonary 78%
          - % bacteriologically confirmed among pulmonary 89%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 52% (36–80)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.25 (0.13–0.42)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 89 <1%
          - on antiretroviral therapy 89 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  230
(17–440)
Estimated % of TB cases with MDR/RR-TB 0.49% (0–1.1) 5.9% (0–14)  
% notified tested for rifampicin resistance     569
MDR/RR-TB cases tested for resistance to second-line drugs   15
Laboratory-confirmed cases MDR/RR-TB: 41, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 7, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2014 83% 18 822
Previously treated cases registered in 2014 78% 1 949
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 64% 14
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
26% (24–28)
TB financing, 2016  
National TB budget (US$ millions) 9.5
Funding source: <1% domestic, 37% international, 63% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data